Author(s): Carvalho, Otavio Valerio de ; Felix, Daniele Mendes ; Tozato, Claudia de Camargo [UNESP] ; Rangel Fietto, Juliana Lopes ; Almeida, Marcia Rogeria de ; Bressan, Gustavo Costa ; Pena, Lindomar Jose ; Silva-Junior, Abelardo
Date: 2018
Persistent ID: http://hdl.handle.net/11449/162913
Origin: Oasisbr
Subject(s): Canine distemper; Antiviral; Azathioprine; Thiopurine; Nucleoside analogue
Made available in DSpace on 2018-11-26T17:34:55Z (GMT). No. of bitstreams: 0 Previous issue date: 2017-06-26
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG)
Background: Canine distemper (CD) is a widespread infectious disease that can severely impact a variety of species in the order Carnivora, as well as non-carnivore species such as non-human primates. Despite large-scale vaccination campaigns, several fatal outbreaks have been reported in wild and domestic carnivore populations. This, in association with expansion of the disease host range and the development of vaccine-escape strains, has contributed to an increased demand for therapeutic strategies synergizing with vaccine programs for effectively controlling canine distemper. 6-methylmercaptopurine riboside (6MMPr) is a modified thiopurine nucleoside with known antiviral properties against certain RNA viruses. Methods: We tested the inhibitory effects of 6MMPr against a wild-type CDV strain infection in cell culture. We measured infectious particle production and viral RNA levels in treated and untreated CDV-infected cells. Ribavirin (RIB) was used as a positive control. Results: Here, we report for the first time the antiviral effects of 6MMPr against canine distemper virus (CDV) in vitro. 6MMPr was able to reduce viral RNA levels and to inhibit the production of infectious CDV particles. The therapeutic selectivity of 6MMPr was approximately six times higher than that of ribavirin. Conclusion: Our results indicate that 6MMPr has high anti-CDV potential and warrants further testing against other paramyxoviruses, as well as clinical testing of the compound against CDV.
Univ Fed Vicosa, Dept Vet, Lab Anim Virol, Av Peter Henry Rolfs S-N, BR-36570000 Vicosa, MG, Brazil
Fundacao Oswaldo Cruz, FIOCRUZ, Lab Virol & Expt Therapy, Aggeu Magalhaes Res Ctr, Av Moraes Rego S-N,Campus UFPE,Cidade Univ, BR-50670420 Recife, PE, Brazil
Univ Estadual Paulista, Biosci Inst, Dept Microbiol & Immunol, Lab Anim & Human Virol, BR-18618970 Botucatu, SP, Brazil
Univ Fed Vicosa, Dept Biochem & Mol Biol, Av Peter Henry Rolfs S-N, BR-36570000 Vicosa, MG, Brazil
Univ Estadual Paulista, Biosci Inst, Dept Microbiol & Immunol, Lab Anim & Human Virol, BR-18618970 Botucatu, SP, Brazil
